TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02089230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK 162
Description: Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle.~Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK 162
Description: Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle.~Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK 162
Description: Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle.~Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I.
Study: NCT00686140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: 400mg/day, twice a day, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice a day, 12 weeks
Study: NCT03716310

Intervention type: DIAGNOSTIC_TEST
Intervention: platelet responsiveness evaluation
Description: Blood samples were anticoagulated with 0.129 mmol/L of sodium citrate and then centrifugated for 10 min at 200 rpm; platelets aggregation was assessed with an AggRAM Advanced Modular System light transmittance aggregometer (Helena Laboratories, Beaumont, Texas, USA). Low-molecular-weight heparin (LMWH) was given at least 8 hours before any blood aggregation sample. Agonist used to initiate aggregation test were: -Adenosine diphosphate (ADP) to assess P2Y12-dependent platelet aggregation; (20 ng) - Arachidonic acid (AA) to assess cyclooxygenase-dependent platelet Adenosine diphosphate aggregation (1 mcg) - thrombin receptor-activating peptide-6 (TRAP-6) to assess protease-activated receptor 1-dependent platelet aggregation. Max aggregation reached (Aggmax), the slope of the curve (slope) and the latency time (lat) were analyzed for each agonist.
Study: NCT02003079

Intervention type: BEHAVIORAL
Intervention: Cystic Fibrosis Questionnaire (Revised) for Teens/Adults
Study: NCT04806828

Intervention type: OTHER
Intervention: Preoperative classification
Description: Score of inguinal hernia
Study: NCT03123146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Behavior-Based Cognitive Behavioral Therapy
Description: Fb-CBT involved nine 2-hour weekly sessions with three to four children in each group and two therapists. Therapy consisted of group activities, individual work in parent-child dyads, group parent training, and social skills exercises.
Study: NCT04107831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Pre-post test design
Study: NCT05351996

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotape
Description: The participants received kinesiotape application three times with one-week intervals. Y strip tape was used. The interventionist applied the band to the rectus femoris muscle with facilitation technique.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-kinesiotape
Description: The participants received sham-kinesiotape application three times with one-week intervals.~In the sham group, the interventionist adhered KT to the rectus femoris transversely, without stretching.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based exercise program
Description: Participants were taught exercise program training. The exercise intervention was based on quadriceps and knee flexor muscle group strengthening, and knee joint range of motion exercises, in their home.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Home-based exercise program
Description: Participants were taught exercise program training. The exercise intervention was based on quadriceps and knee flexor muscle group strengthening, and knee joint range of motion exercises, in their home.
Study: NCT05139667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Topical
Description: topical tacrolimus and corticosteroids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid Topical
Description: topical tacrolimus and corticosteroids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid Topical
Description: topical tacrolimus and corticosteroids
Study: NCT01980407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, leucovorin, oxaliplatin
Description: S-1 (20mg), capsule, 40-60mg, bid, p.o., day1-14； Leucovorin (15 mg), tablet, 30mg,Bid, p.o., day1-14; Oxaliplatin (50 mg), injection 85mg/m2, day1.
Study: NCT00820274

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: amniotic membranes
Description: The amniotic membrane is taken with a sterile crowbar then applied side foetal face against the ulcer and displayed in a homogeneous way
Study: NCT01730885

Intervention type: OTHER
Group type: OTHER
Intervention: Comparison of different Blood Glucose Meters
Study: NCT03019354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow nasal oxygen
Description: Using high-flow nasal oxygen 10 L/min before anesthesia induction, then using high-flow nasal oxygen 30-50 L/min during intravenous general anesthesia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen mask
Description: Using oxygen mask with oxygen flow 10 L/min before and during intravenous general anesthesia.
Study: NCT04272775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets.
Study: NCT02687256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended Wear infusion set
Description: For two of the 4 weeks the Extended Wear insulin infusion set will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended Wear infusion set
Description: For two of the 4 weeks the Extended Wear insulin infusion set will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended Wear infusion set
Description: For two of the 4 weeks the Extended Wear insulin infusion set will be used.
Study: NCT04978714

Intervention type: PROCEDURE
Intervention: Cystocele repair
Description: Fascial repair for endopelvic fascia and anterior colporrhaphy
Study: NCT04021017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Hemihydrate Transdermal System
Description: Participants who have had their first period or have a bone age greater than or equal to 14 years will receive PrClimara® 25 (estradiol hemihydrate transdermal system - 25 mcg/day) as a weekly patch, for 24 months. Participants who have not yet had their first period and have a bone age below 14 years will receive an increasing dose of estrogen. These participants will be initiated on graduated dose of transdermal 17-β estradiol patches: 3.1 mcg/day (1/8 patch) for first six-months, 6.2 mcg/day (1/4 patch) for second six-months, 12.5 mcg/day (1/2 patch) for third six-months and 25 mcg/day (full patch) for final six-months.
Study: NCT03767179

Intervention type: DIAGNOSTIC_TEST
Intervention: study
Description: procalcitonin, sedimentation, CRP, leukocyte identification
Study: NCT02687256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended Wear infusion set
Description: For two of the 4 weeks the Extended Wear insulin infusion set will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended Wear infusion set
Description: For two of the 4 weeks the Extended Wear insulin infusion set will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended Wear infusion set
Description: For two of the 4 weeks the Extended Wear insulin infusion set will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended Wear infusion set
Description: For two of the 4 weeks the Extended Wear insulin infusion set will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended Wear infusion set
Description: For two of the 4 weeks the Extended Wear insulin infusion set will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended Wear infusion set
Description: For two of the 4 weeks the Extended Wear insulin infusion set will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Infusion set
Description: For two of the 4 weeks the Standard infusion set will be used

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Infusion set
Description: For two of the 4 weeks the Standard infusion set will be used

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Infusion set
Description: For two of the 4 weeks the Standard infusion set will be used

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Infusion set
Description: For two of the 4 weeks the Standard infusion set will be used

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Infusion set
Description: For two of the 4 weeks the Standard infusion set will be used
Study: NCT01573806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Exenatide, dosed subcutaneously every 12 hours for 4 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exenatide vehicle
Description: Exenatide vehicle, dosed subcutaneously every 12 hours for 4 doses
Study: NCT01751126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOVA22007 ''Ciclosporin''
Description: Sterile, ophthalmic cationic oil-in-water emulsion containing 1 mg/ml Ciclosporin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOVA22007 ''Ciclosporin''
Description: Sterile, ophthalmic cationic oil-in-water emulsion containing 1 mg/ml Ciclosporin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile, drug-free, cationic ophthalmic oil-in-water emulsion containing 0 mg/ml Ciclosporin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile, drug-free, cationic ophthalmic oil-in-water emulsion containing 0 mg/ml Ciclosporin.
Study: NCT03808779

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: Patients were supine with the neck exposure completely during the procedure. Local anesthesia with 1% lidocaine was injected at the subcutaneous puncture site and the thyroid anterior capsule. If the distance between the tumor and critical cervical structures was less than 5 mm, normal saline was injected to form at least 1 cm distance between the tumor and the critical structure to prevent the unwilling thermal injury. RFA was performed using the moving-shot technique and RFA power was 5 W, if a transient hyperechoic zone did not form at the electrode tip within 5-10 seconds. The RFA extent exceeded the tumor edge to prevent marginal residue and recurrence. The ablation was terminated when all portions of the target ablation area had changed to hyperechoic zones.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Surgery
Description: Patient is performed total thyroidectomy or thyroid lobectomy depending on the intraoperative situation, disease condition and comprehensive judge by surgeon. Patients are routinely disinfected and spread the drapes after general anesthesia. Neck skin, fat and placenta muscle are incised and separated successively. The flap is separated to the upper edge of thyroid cartilage, neck white line is incised and anterior muscle group is separated. Then both sides thyroid lobes are exposed. Cut off the isthmus, ligature the thyroid artery, cut off the upper pole. Ligature and cut off the ipsilateral thyroid vein. Reveal and protect the ipsilateral recurrent laryngeal nerve and the parathyroid gland during the entire process.
Study: NCT02093767

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synergy1
Description: The prebiotic preparation, Synergy-1, consists of 1:1 inulin and oligosaccharide. The chicory derived inulin has a degree of polymerization (DP) of 10 to 60 (average DP of 25). The oligofructose is produced by partial enzymatic hydrolysis of chicory derived inulin and has a DP ranging between 3 and 7 (average DP of 4).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synergy1
Description: The prebiotic preparation, Synergy-1, consists of 1:1 inulin and oligosaccharide. The chicory derived inulin has a degree of polymerization (DP) of 10 to 60 (average DP of 25). The oligofructose is produced by partial enzymatic hydrolysis of chicory derived inulin and has a DP ranging between 3 and 7 (average DP of 4).
Study: NCT02993445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternate Nostril Breathing
Study: NCT01011465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after the full amount in the spray bottle has been used. Duration of administration is anticipated to be 2-5 minutes
Study: NCT02993445

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot Reflexology
Study: NCT01011465

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Social support
Description: Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. If instructed to bring a same-sex close friend (excluding spouses, participants are joined by their support partners join participants at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.
Study: NCT02687256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Infusion set
Description: For two of the 4 weeks the Standard infusion set will be used

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Infusion set
Description: For two of the 4 weeks the Standard infusion set will be used

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Infusion set
Description: For two of the 4 weeks the Standard infusion set will be used

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Infusion set
Description: For two of the 4 weeks the Standard infusion set will be used
Study: NCT02687256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Study: NCT01011465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support
Description: Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. If instructed to bring a same-sex close friend (excluding spouses, participants are joined by their support partners join participants at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.
Study: NCT02687256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Study: NCT01011465

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Social support
Description: Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. If instructed to bring a same-sex close friend (excluding spouses, participants are joined by their support partners join participants at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.
Study: NCT02687256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Study: NCT02272868

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbial transplant
Description: Pretransplant regimen(rifaxamin+omeprazole+miralax) + Donor feces transplant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Pretransplant regimen(rifaximin+omeprazole+miralax) +Normal Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifaximin+omeprazole+miralax

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rifaximin+omeprazole+miralax
Study: NCT01826240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT+SPI
Description: Safety Planning Intervention (SPI), a very brief intervention focused on identifying personalized coping strategies to manage acute suicidality, is combined with Mindfulness-Based Cognitive Therapy (MBCT), a group intervention comprised of mindfulness training and cognitive therapy techniques. Treatment lasts 9 weeks.
Study: NCT01011465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support
Description: Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. If instructed to bring a same-sex close friend (excluding spouses, participants are joined by their support partners join participants at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No Social Support
Description: Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. They are then instructed to bring a same-sex close friend (excluding spouses) with them, or to come alone. If they come to the laboratory without a friend, they engage in all the laboratory procedures without a friend present.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No Social Support
Description: Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. They are then instructed to bring a same-sex close friend (excluding spouses) with them, or to come alone. If they come to the laboratory without a friend, they engage in all the laboratory procedures without a friend present.
Study: NCT04536311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: internal fixation of mulitiple rib fracture
Description: The dislocated rib fracture was anatomically reduced, and then fixed with appropriate equipment to prevent the fracture from being displaced again
Study: NCT00871689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: IL-2 will be administered (9 million units; 5 million units if weight is less than 45 kg) every other day beginning on day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg over 1 hour intravenously (IV) on days -7 and -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 25 mg/m\^2 intravenously (IV) over 1 hour on days -7 through -5.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: On day 0, transplantation will occur with double T-cell depleted (TCD) umbilical cord blood (UCB) units

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: administered on days -5 through -2; 330 cGy daily
Study: NCT05634239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Interview, clinical examination and health education conducted by the clinic nurse.~Appointment with the physiotherapist including the assessment of physical functioning, use of assistive mobility devices, and amount of help needed in activities of daily living.
Study: NCT01579604

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve reconstruction
Description: Under general anesthetic, the surgeon will make a cut on the back (dorsal) part of the forearm. The radial nerve will be identified and specifically the branches which control the supinator muscle and the remainder of the radial nerve (Posterior interosseous nerve or PIN). . The PIN branch will be stimulated to ensure that it is non-functional. Then, the supinator branch will be stimulated to ensure it is functioning and is appropriate for transfer. If appropriate, the supinator branch will be severed and connected to the EDC branch under the operating room microscope. After the surgery, the patient will be placed into a splint including the forearm and hand for 2-3 weeks.
Study: NCT02342522

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: An automated autoRIC™ cuff will be placed on the upper arm and inflated to 200mmHg for 5 minutes and then deflated for 5 minutes, a cycle which will be undertaken 4 times in total.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: An automated autoRIC™ cuff will be placed on the upper arm and a simulated inflation and deflation protocol will be applied.
Study: NCT03888339

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available high abutments placement
Description: Patients will be randomly selected for the commercially available high abutments option. Two or three implants will be placed following the drilling protocol suggested by the manufacturer. Implants will be placed 0.5mm subcrestal. Once the implants have been placed, periapical radiographs and clinical pictures will be taken. Implants will be uncovered 10 weeks after being placed. After performing the incision and elevation a minimal flap, conventional high transmucosal abutments will be screwed using the torque recommended by the manufacturer. Once the abutments have been screwed, periapical radiographs and clinical pictures will be taken. The abutments will not be unscrewed thereafter throughout the study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified shape abutments
Description: Patients will be randomly selected for the modified shape abutments option. Two or three implants will be placed following the drilling protocol suggested by the manufacturer. Implants will be placed 0.5mm subcrestal. Once the implants have been placed, periapical radiographs and clinical pictures will be taken. Implants will be uncovered 10 weeks after being placed. After performing the incision and elevation a minimal flap, modified high transmucosal abutments will be screwed using the torque recommended by the manufacturer. Once the abutments have been screwed, periapical radiographs and clinical pictures will be taken. The abutments will not be unscrewed thereafter throughout the study.
Study: NCT02606279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan
Description: Valsartan will be given in increasing doses (from 40 mg to 80 mg) to those in the valsartan arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo